Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Viking Therapeutics Inc VKTX
News
-
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
This weight-loss ETF has performed well in its -2-
Healthcare stocks fade as obesity-drug optimism fades
Thinking about trading options or stock in Micron Technology, Apple, Viking Therapeutics, Marvell Technology, or Vertiv Holdings?
Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock's a buy.
Thinking about trading options or stock in NVIDIA, Vale, Viking Therapeutics, GigaCloud Technology, or Crowdstrike Holdings?
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Thinking about trading options or stock in Advanced Micro Devices, Amazon.com, Intel, GSK, or Viking Therapeutics?
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Here's how investors can ride along as a major global commodity market shifts away from China
Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount
This biotech ETF sees 'breakout' while U.S. small-cap technology stocks lag
Thinking about buying stock in Volcon, Abeona Therapeutics, Agenus, Viking Therapeutics, or Compugen?
Viking Therapeutics' promising weight-loss drug data makes the company a takeover target
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
Viking Therapeutics' stock more than doubles as investors cheer cheap entry to weight-loss-drug craze
Viking Therapeutics Announces Proposed Public Offering of Common Stock
Thinking about trading options or stock in Alphabet Inc, Autozone, Zoom Video Communications, TransMedics Group, or Viking Therapeutics?
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity